Coryfea Biosciences Oy is a limited company based in Helsinki, registered in 2023. In the financial year ending 31.12.2024, revenue was 163 t€ and operating profit 78 t€; equity ratio 99.7 %. Its taxable income in 2024 was 78 t€ and its income taxes 16 t€.
Helsinki: 289 new companies in 30 days
- Mixedtape Group OyRuokaravintolat
- Bella Creative OyMuu esittävä taide
- LHT Solutions OyPuhelinpalvelukeskusten toiminta
Financials
| Key figures | 31.12.2024 | 31.12.2023 |
|---|---|---|
| Revenue | 163 t€ | 76 t€ |
| Revenue change | 115,4 % | – |
| EBITDA | 78 t€ | 153 € |
| EBITDA % | 47,9 % | 0,2 % |
| Operating profit | 78 t€ | 153 € |
| Operating margin | 47,9 % | 0,2 % |
| Net profit | 78 t€ | 153 € |
| Personnel costs | 67 t€ | 69 t€ |
| Equity ratio | 99,7 % | 1,3 % |
| Quick ratio | 332,23 | 1,01 |
| Current ratio | 332,23 | 1,01 |
| Debt to revenue | 0,1 % | 15,7 % |
| Return on equity | 99,8 % | 100,0 % |
| Balance sheet total | 78 t€ | 12 t€ |
| Equity | 78 t€ | 153 € |
| Cash and bank | 78 t€ | 11 t€ |
Balance sheet
Income statement and balance sheet
Income statement
| 31.12.2024 | 31.12.2023 | |
|---|---|---|
| Turnover | 163 t€ | 76 t€ |
| Personnel expenses | -67 t€ | -69 t€ |
| Other operating expenses | -17 t€ | -6 740 € |
| Operating profit (loss) | 78 t€ | 153 € |
| Financial income and expenses + (-) | 1 € | 0 € |
| Profit (loss) before appropriations and taxes | 78 t€ | 153 € |
| Income taxes | -68 € | 0 € |
| Profit (loss) for the financial year | 78 t€ | 153 € |
Balance sheet
| 31.12.2024 | 31.12.2023 | |
|---|---|---|
| Receivables | 556 € | 1 459 € |
| Cash in hand and at banks | 78 t€ | 11 t€ |
| Current assets | 78 t€ | 12 t€ |
| Assets | 78 t€ | 12 t€ |
| Capital and reserves | 78 t€ | 153 € |
| Short-term liabilities | 236 € | 12 t€ |
| Liabilities | 236 € | 12 t€ |
All financial statement items (28)
| 31.12.2024 | 31.12.2023 | |
|---|---|---|
| Turnover | 163 t€ | 76 t€ |
| Personnel expenses | -67 t€ | -69 t€ |
| Other operating expenses | -17 t€ | -6 740 € |
| Operating profit (loss) | 78 t€ | 153 € |
| Financial income and expenses + (-) | 1 € | 0 € |
| Profit (loss) before appropriations and taxes | 78 t€ | 153 € |
| Income taxes | -68 € | 0 € |
| Profit (loss) for the financial year | 78 t€ | 153 € |
| Receivables | 556 € | 1 459 € |
| Cash in hand and at banks | 78 t€ | 11 t€ |
| Current assets | 78 t€ | 12 t€ |
| Assets | 78 t€ | 12 t€ |
| Capital and reserves | 78 t€ | 153 € |
| Short-term liabilities | 236 € | 12 t€ |
| Liabilities | 236 € | 12 t€ |
| Other short-term receivables | 144 € | 547 € |
| Other current liabilities | 0 € | 10 t€ |
| Retained earnings | 153 € | 0 € |
| Short-term prepayments and accrued income | 411 € | 911 € |
| Short-term accounts payable | 236 € | 1 398 € |
| Short-term sales receivables | 0 € | 0 € |
| Profit (loss) for the period, equity | 78 t€ | 153 € |
| Short-term receivables | 556 € | 1 459 € |
| Wages and salaries | -60 t€ | -66 t€ |
| Liabilities | 78 t€ | 12 t€ |
| Other interest and financial income from non-group companies | 1 € | 0 € |
| Other social security expenses | -1 813 € | -1 308 € |
| Pension expenses | -5 628 € | -1 470 € |
From financial statements filed digitally (XBRL) with the Finnish Patent and Registration Office; ratios calculated from them. Equity ratio = (equity + accumulated appropriations) / (balance sheet total − advances received).
Taxes
Measured by taxable income, Coryfea Biosciences Oy is in the upper half of the industry class research and experimental development on natural sciences and engineering (326 companies with taxable income; median 34 t€, 2,3 times the median).
Taxable income is the profit as calculated for taxation, not revenue. Public data from the Finnish Tax Administration; figures for 2025 are published in November 2026.